5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated with Citalopram in a 12-Weeks Follow Up Study

Journal of Clinical Psychopharmacology

Volumn 23, Issue 6, 2003, Pages 563-567

  Arias, Bárbara ^a   Catalán, Rosa ^b   Gastó, Cristóbal ^b   Gutiérrez, Blanca ^a   Fañanás, Lourdes ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; SEROTONIN TRANSPORTER;

ADULT; ALLELE; ARTICLE; CONDITIONING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAMILTON SCALE; HOMOZYGOSITY; HUMAN; MAJOR DEPRESSION; MALE; PATIENT CARE; PRIORITY JOURNAL; REMISSION; SAMPLING;

ADULT; CARRIER PROTEINS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); PSYCHOLOGICAL TESTS; REMISSION INDUCTION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0344896572     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000095350.32154.73     Document Type: Article

References (29)

1. Martin RM, Hilton SR, Kerry SM, et al. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. Bmj. 1997;314:646-651.
2. Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry. 2000;61:712-721.
3. Quitkin FM, Liebowitz MR, Stewart JW, et al. 1-Deprenyl in atypical depressives. Arch Gen Psychiatry. 1984;41:777-781.
4. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry. 2002;7(Supp 1):S23-28.
5. Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet. 1999; 354:1369-1375.
6. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996;11(Suppl 1):5-11.
7. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol. 1995;10(Suppl 1):15-21.
8. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet. 2000;355:1358-1361.
9. Steimer W, Muller B, Leucht S, et al. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta. 2001;308:33-41.
10. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615-1616.
11. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511.
12. Zanardi R, Benedetti F, Di Bella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 2000;20:105-107.
13. Zanardi R, Serretti A, Rossini D, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 2001;50:323-330.
14. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23: 587-590.
15. Serretti A, Zanardi R, Rossini D, et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry. 2001;6:586-592.
16. Rausch JL, Johnson ME, Fei YJ, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry. 2002;51:723-732.
17. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11:215-219.
18. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. Eur J Pharmacol. 2002;438:117-128.
19. Mancama D, Kerwin RW. Role of pharmacogenetics in individualising treatment with SSRIs. CNS Drugs. 2003;17:1-10.
20. Allison DB. Transmission-disequilibrium tests for quantitative traits. Am J Hum Genet 1997;60:676-690.
21. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531.
22. Spitzer RL WJ, Gibbon M, First MEB. Structured clinical interview for DSM-III-R. Washington DC: American Psychiatric Press, 1990.
23. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolites. J Chromatogr B Biomed Appl. 1996;675: 83-88.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1970;23:51-56.
25. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996; 16:307-314.
26. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991; 48:851-855.
27. Sanchez C, Hyttel J. Comparison of the effects of antidepressant and their metabolites on re-uptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999;19:467-489.
28. Enserick M. Can placebo be the cure. Science. 1999; 184:196-204.
29. Weiss M, Gaston I, Propst A, et al. The role of alliance in the pharmacological treatment of depression. Journal of Clinical Psychiatry. 1997;58:196-204.